Latest news with #RajivShukla
India.com
5 days ago
- Sport
- India.com
BCCI Vice President Rajeev Shukla denies any political agenda behind shifting IPL venue out of Kolkata, it was shifted due to….
BCCI Vice President Rajeev Shukla denies any political agenda behind shifting IPL venue out of Kolkata, it was shifted due to.... New Delhi: Board of Control for Cricket in India (BCCI) Vice President Rajeev Shukla has categorically rejected the political allegations raised regarding the change in the playoff and final venue of the Indian Premier League (IPL) 2025. He clearly said that there is no political agenda behind this decision, but weather conditions and broadcasting concerns were the main reasons. Schedule changed due to India-Pakistan tension IPL 2025 had to be postponed for a week due to increased tension on the border between India and Pakistan. After this, the BCCI released a new schedule for the playoffs and final. Earlier Kolkata was to host the final, but it was shifted to Ahmedabad. Similarly, the Qualifier-1 and Eliminator matches to be played in Hyderabad were shifted to New Chandigarh. Questions raised on shift from Kolkata to Ahmedabad The BCCI had to face severe criticism over the decision to shift the IPL final from Eden Gardens in Kolkata. Many reports even said that there is a political motive behind this decision, which raised questions about the fairness of the game. 'Weather became the main reason' – Rajiv Shukla Rajiv Shukla termed these allegations as baseless and said that the decision to shift the venue was taken on the basis of weather apprehensions. He said, 'If IPL 2025 had been held as per its earlier schedule, the final would have been held in Kolkata and Hyderabad would have hosted the playoffs. But when the tournament was postponed, the change was made keeping the weather in mind.' Broadcasters also had a demand Rajiv Shukla also said that broadcasters had also recommended changing the venue in view of the possible loss. He said that keeping in mind the possibility of rain, the broadcasters requested to shift the matches to cities where the weather was more likely to be favorable. 'No place for politics' Shukla said in a statement to ANI, 'Politics has no place in the decision to change the venue of the IPL 2025 final. It was a completely practical and weather-related decision to ensure the success of the tournament.'
Yahoo
27-05-2025
- Business
- Yahoo
Longevity Health Holdings, Inc. Announces Successful Fundraising Via ATM Sale
Pittsburgh, PA, May 27, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE) ('XAGE,' the 'Company,' 'we' or 'our'), a company dedicated to advancing human longevity and healthy aging through regenerative bio-aesthetics, diagnostics, and nutrition, today announced the successful sale of 479,621 shares of its common stock at an average price of $4.08 per share through its at-the-market (ATM) equity offering facility. Gross proceeds from the ATM sales totaled approximately $1.96 million, prior to deducting fees and expenses. Assuming no growth beyond the Company's pro forma consolidated FY24 sales and not factoring in the planned 20/20 merger, this financing extends XAGE's cash runway into Q1 FY26. 'We are pleased to strengthen our balance sheet further as we move forward with our planned merger with 20/20 and the continued delivery of innovative longevity products to our customers,' said Rajiv Shukla, Chairman and Chief Executive Officer of XAGE. 'This successful ATM offering reflects continued investor confidence in our vision and growth strategy.' About XAGE: Longevity Health Holdings is focused on longevity and healthy aging, encompassing the latest scientific advances in regenerative bio-aesthetics, diagnostics, and nutrition. Our products are designed to help people look and feel their best at any age. The Company currently offers two regenerative technologies for skin and hair health: Carmell Secretome™ and Elevai Exosomes™. Carmell Secretome™ is a powerful blend of growth factors, proteins, peptides and bio-lipids derived from allogeneic human platelets, the body's principal cells responsible for healing and regeneration. The Elevai ExosomesTM are derived from human umbilical mesenchymal stem cells, which are known to contain a greater number of proteins than exosomes from non-stem cell sources. About 20/20: 20/20 BioLabs develops and commercializes innovative laboratory tests for the early detection and the proactive management of chronic disease risk. It offers a multi-cancer early detection blood test available in the U.S., which can be accessed at home or at retail locations. This quarter, 20/20 also expects to introduce a new blood test for monitoring chronic inflammation, which contributes to eight of the ten leading causes of death in America, as well as skin disorders. Forward-Looking Statements: This press release contains forward-looking statements that are based on beliefs, assumptions and information currently available. In some cases, you can identify forward-looking statements by the following words: 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology. However, not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the launch and commercialization of new products and tests by XAGE and 20/20; the structure, timing and completion of the proposed merger with 20/20 (the 'Merger'); expectations regarding the ability of the combined company to meet the Nasdaq initial listing rules; and the future operations and products of the combined company. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, risks related to (i) the risk that the conditions to the closing of the proposed Merger (the 'Closing') are not satisfied, including the failure to timely obtain stockholder approval for the transaction, if at all; (ii) uncertainties as to the timing of the consummation of the proposed Merger and the ability of each company to consummate the proposed Merger; (iii) risks related to XAGE's ability to maintain its listing on the Nasdaq Capital Market and to manage its operating expenses and its expenses associated with the proposed Merger pending the Closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed Merger; (v) the risk that as a result of adjustments to the exchange ratio, each company's stockholders could own more or less of the combined company than is currently anticipated; (vi) risks related to the market price of XAGE's common stock relative to the value suggested by the exchange ratio; (vii) unexpected costs, charges or expenses resulting from the transaction; (viii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed Merger; (ix) risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance the commercialization, development and marketing of its products; (x) risks associated with the possible failure to realize certain anticipated benefits of the proposed Merger, including with respect to future financial and operating results; (xi) the risk that the concurrent financing is not consummated prior to the Closing; (xii) risks related to the diversion of management's attention from our ongoing business; (xiii) the risk of unknown liabilities arising after the Merger; (xiv) the ability to recognize anticipated benefits from our commercial products, R&D pipeline, distribution agreements, changes in applicable laws or regulations; (xv) the possibility that we may be adversely affected by other economic, business, and/or competitive factors, and (xvi) other risks and uncertainties, those described under the header 'Risk Factors' in the Annual Report on Form 10-K filed by XAGE with the U.S. Securities and Exchange Commission (the 'SEC') on March 31, 2025, and in our other reports filed with the SEC. Most of these factors are outside of XAGE's control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. Except as required by law, we undertake no obligation to publicly update any forward-looking statement contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. No Offer or Solicitation This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor a solicitation of any vote or approval with respect to the proposed transaction or otherwise. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U S. Securities Act of 1933, as amended, and otherwise in accordance with applicable law. Additional Information and Where to Find It This communication relates to the proposed Merger involving 20/20 and XAGE and may be deemed to be solicitation material in respect of the proposed Merger. In connection with the proposed Merger, XAGE has filed a registration statement on Form S-4 (the 'Form S-4') that contains a proxy statement (the 'Proxy Statement') and prospectus. This communication is not a substitute for the Form S-4, the Proxy Statement, or for any other document that XAGE may file with the SEC and or send to XAGE's stockholders in connection with the proposed Merger. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF XAGE ARE URGED TO READ THE FORM S-4, THE PROXY STATEMENT AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT XAGE, THE PROPOSED MERGER AND RELATED MATTERS. Investors and security holders will be able to obtain free copies of the Form S-4, the Proxy Statement and other documents filed by XAGE with the SEC through the website maintained by the SEC at Copies of the documents filed by XAGE with the SEC will also be available free of charge on XAGE's website at or by contacting Bryan Cassaday at bcassaday@ Participants in the Solicitation XAGE, 20/20, and their respective directors and certain of their executive officers may be considered participants in the solicitation of proxies from XAGE's stockholders with respect to the proposed Merger under the rules of the SEC. Information about the directors and executive officers of XAGE is set forth in its Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 31, 2025, subsequent Quarterly Reports on Form 10-Q and other documents that may be filed from time to time with the SEC. Additional information regarding the persons who may be deemed participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in the Form S-4, the Proxy Statement and other relevant materials to be filed with the SEC when they become available. You may obtain free copies of these documents as described above. Contact: Bryan Cassadaybcassaday@ CONTACT: Contact: Bryan Cassaday bcassaday@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-05-2025
- Business
- Yahoo
Longevity Health Holdings Announces Continued Nasdaq Listing to Complete Merger With 20/20 Biolabs
PITTSBURGH, May 21, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE) ('XAGE,' the 'Company,' 'we,' 'us,' or 'our'), a company focused on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition, today announced that it has received a favorable decision from the Nasdaq Hearings Panel (the 'Panel') granting the Company's request to continue its listing on The Nasdaq Stock Market ('Nasdaq') subject to the satisfaction of the Nasdaq initial listing rules for the combined company following the proposed merger with 20/20 BioLabs, Inc. ('20/20') on or before September 2, 2025. This decision follows the Panel's comprehensive review of the Company's recent business developments, financial disclosures, and proposed merger with 20/20. As part of its strategic plan, XAGE presented its intention to merge with 20/20 and effect a 1-for-30 reverse stock split to address Nasdaq's listing requirements. The Company filed the S-4 registration statement for the proposed merger on May 8, 2025, and effected the reverse stock split on May 12, 2025. Based on a review of both companies' financial statements and pro forma projections, the Panel has granted XAGE an exception to allow the Company time to complete its merger with 20/20 and to demonstrate the combined company's compliance with Nasdaq's initial listing rules on or before September 2, 2025. 'We are pleased to have received the Panel's decision and remain focused on completing our merger with 20/20 BioLabs,' said Rajiv Shukla, Chairman and Chief Executive Officer of XAGE. 'We thank our stockholders and partners for their continued support as we execute our growth strategy and advance our mission to deliver innovative longevity solutions.' About XAGE: Longevity Health Holdings is focused on longevity and healthy aging, encompassing the latest scientific advances in regenerative bio-aesthetics, diagnostics, and nutrition. Our products are designed to help people look and feel their best at any age. The Company currently offers two regenerative technologies for skin and hair health: Carmell Secretome™ and Elevai Exosomes™. Carmell Secretome™ is a powerful blend of growth factors, proteins, peptides and bio-lipids derived from allogeneic human platelets, the body's principal cells responsible for healing and regeneration. The Elevai Exosomes™ are derived from human umbilical mesenchymal stem cells, which are known to contain a greater number of proteins than exosomes from non-stem cell sources. About 20/20: 20/20 Biolabs develops and commercializes innovative laboratory tests for the early detection and the proactive management of chronic disease risk. It offers a multi-cancer early detection blood test available in the U.S., which can be accessed at home or at retail locations. This quarter, 20/20 also expects to introduce a new blood test for monitoring chronic inflammation, which contributes to eight of the ten leading causes of death in America, as well as skin disorders. Forward-Looking Statements: This press release contains forward-looking statements that are based on beliefs, assumptions and information currently available. In some cases, you can identify forward-looking statements by the following words: 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology. However, not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the launch and commercialization of new products and tests by XAGE and 20/20; the structure, timing and completion of the proposed merger with 20/20 (the 'Merger'); expectations regarding the ability of the combined company to meet the Nasdaq initial listing rules; ; and the future operations and products of the combined company. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, risks related to (i) the risk that the conditions to the closing of the proposed Merger (the 'Closing') are not satisfied, including the failure to timely obtain stockholder approval for the transaction, if at all; (ii) uncertainties as to the timing of the consummation of the proposed Merger and the ability of each company to consummate the proposed Merger; (iii) risks related to XAGE's ability to maintain its listing on the Nasdaq Capital Market and to manage its operating expenses and its expenses associated with the proposed Merger pending the Closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed Merger; (v) the risk that as a result of adjustments to the exchange ratio, each company's stockholders could own more or less of the combined company than is currently anticipated; (vi) risks related to the market price of XAGE's common stock relative to the value suggested by the exchange ratio; (vii) unexpected costs, charges or expenses resulting from the transaction; (viii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed Merger; (ix) risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance the commercialization, development and marketing of its products; (x) risks associated with the possible failure to realize certain anticipated benefits of the proposed Merger, including with respect to future financial and operating results; (xi) the risk that the concurrent financing is not consummated prior to the Closing; (xii) risks related to the diversion of management's attention from our ongoing business; (xiii) the risk of unknown liabilities arising after the Merger; (xiv) the ability to recognize anticipated benefits from our commercial products, R&D pipeline, distribution agreements, changes in applicable laws or regulations; (xv) the possibility that we may be adversely affected by other economic, business, and/or competitive factors, and (xvi) other risks and uncertainties, those described under the header 'Risk Factors' in the Annual Report on Form 10-K filed by XAGE with the U.S. Securities and Exchange Commission (the 'SEC') on March 31, 2025, and in our other reports filed with the SEC. Most of these factors are outside of XAGE's control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. Except as required by law, we undertake no obligation to publicly update any forward-looking statement contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor a solicitation of any vote or approval with respect to the proposed transaction or otherwise. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U S. Securities Act of 1933, as amended, and otherwise in accordance with applicable communication relates to the proposed Merger involving 20/20 and XAGE and may be deemed to be solicitation material in respect of the proposed Merger. In connection with the proposed Merger, XAGE has filed a registration statement on Form S-4 (the 'Form S-4') that contains a proxy statement (the 'Proxy Statement') and prospectus. This communication is not a substitute for the Form S-4, the Proxy Statement, or for any other document that XAGE may file with the SEC and or send to XAGE's stockholders in connection with the proposed Merger. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF XAGE ARE URGED TO READ THE FORM S-4, THE PROXY STATEMENT AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT XAGE, THE PROPOSED MERGER AND RELATED MATTERS. Investors and security holders will be able to obtain free copies of the Form S-4, the Proxy Statement and other documents filed by XAGE with the SEC through the website maintained by the SEC at Copies of the documents filed by XAGE with the SEC will also be available free of charge on XAGE's website at or by contacting Bryan Cassaday at bcassaday@ 20/20, and their respective directors and certain of their executive officers may be considered participants in the solicitation of proxies from XAGE's stockholders with respect to the proposed Merger under the rules of the SEC. Information about the directors and executive officers of XAGE is set forth in its Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 31, 2025, subsequent Quarterly Reports on Form 10-Q and other documents that may be filed from time to time with the SEC. Additional information regarding the persons who may be deemed participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in the Form S-4, the Proxy Statement and other relevant materials to be filed with the SEC when they become available. You may obtain free copies of these documents as described above. Contact: Bryan Cassadaybcassaday@
Mint
11-05-2025
- Sport
- Mint
IPL 2025 final to be moved from Kolkata to Ahmedabad due to rain threat: Reports
The final of the Indian Premier League 2025 might see a change in the venue, in addition to the change in date. Inclement weather is believed to be the reason for the change in venue, according to PTI reporters. Ahmedabad's Narendra Modi Stadium is believed to be the frontrunner to host the final. The home venue of the defending champions hosting the final has been the norm in IPL. Kolkata's Eden Gardens, the home venue of the defending champions Kolkata Knight Riders, was originally scheduled to host the final on May 25. Hosting the final on May 25 is out of the question, given the one-week suspension of the league from May 9 due to border tensions between India and Pakistan. The two countries agreed to have a ceasefire on May 10. However, the availability of overseas players and other logistical issues mean that the league is expected to resume on May 15 or May 16. Speaking to Press Trust of India (PTI), Rajiv Shukla, the vice-president of BCCI said that no decision has been taken yet. "No decision has been taken yet. The BCCI officials are working on the situation. The tournament was suspended for a week, and yesterday there was a ceasefire. The tournament will be restarted soon" According to AccuWeather, there is a high chance of precipitation in Kolkata during the final week of May. Date Chance of Rain Chance of Thunderstorms May 25 (Sunday) 70 % 40 % May 30 (Friday) 61 % 34 % May 31 (Saturday) 55 % 33 % June 1 (Sunday) 40 % 20 % Kolkata had already witnessed one rain abandonment this season. The league game between Kolkata Knight Riders and Punjab Kings on April 26 was called off due to rain during the 2nd innings. Stay updated on all the action from the IPL 2025. Check the IPL 2025 Schedule, track the latest IPL 2025 Points Table, and follow the top performers with the Orange Cap and Purple Cap.
New Indian Express
09-05-2025
- Sport
- New Indian Express
IPL suspended for one week amid escalating tensions between India and Pakistan
WITH tensions escalating between India and Pakistan, the ongoing edition of the Indian Premier League (IPL) has ground to a halt, at least for the time being. The BCCI made the decision public after informing the franchises earlier on Friday morning. 'The decision was taken by the IPL Governing Council after due consultation with all key stakeholders following the representations from most of the franchisees, who conveyed the concern and sentiments of their players, and also the views of the broadcaster, sponsors and fans; while the BCCI reposes full faith in the strength and preparedness of our armed forces, the Board considered it prudent to act in the collective interest of all stakeholders,' the statement read. This decision came less than 15 hours after the match between Punjab Kings and Delhi Captials in Dharamsala was called off midway after a series off projectiles from Pakistan and a subsequent blackout in bordering states. The BCCI top brass met on Friday morning and the final decision was made. On Thursday night, Arun Dhumal, the IPL Governing Council chair, had told this daily that they are assessing the situation. BCCI vice-president, Rajiv Shukla, had said: "Today there were security concerns in Jammu and Pathankot, which were close to Dharamsala, that is why we called off the match. Tomorrow we don't know what will happen, based on that we will take a decision. We are arranging a special train tomorrow (Friday) for everyone to leave safely.'
